These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16191235)

  • 1. Prevention of stroke recurrence.
    Gorelick PB
    Int Psychogeriatr; 2003; 15 Suppl 1():167-71. PubMed ID: 16191235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy to prevent recurrent stroke: Three good options.
    Mansoor AH; Mujtaba MT; Silver B
    Cleve Clin J Med; 2013 Dec; 80(12):787-95. PubMed ID: 24307163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 5. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
    Hankey GJ
    Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulation and antiaggregation in neurological patients].
    Arnold M; Nedeltchev K; Mattle HP
    Ther Umsch; 2003 Jan; 60(1):33-5. PubMed ID: 12638476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet agents for stroke prevention following transient ischemic attack.
    Weinberger J
    South Med J; 2008 Jan; 101(1):70-8. PubMed ID: 18176296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
    Furlan AJ
    Stroke; 2009 May; 40(5):1942-3. PubMed ID: 19299635
    [No Abstract]   [Full Text] [Related]  

  • 14. A benefit-risk assessment of agents used in the secondary prevention of stroke.
    MacWalter RS; Shirley CP
    Drug Saf; 2002; 25(13):943-63. PubMed ID: 12381215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
    Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
    Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
    Redman AR; Ryan GJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
    Murphy SJX; Naylor AR; Ricco JB; Sillesen H; Kakkos S; Halliday A; de Borst GJ; Vega de Ceniga M; Hamilton G; McCabe DJH
    Eur J Vasc Endovasc Surg; 2019 Feb; 57(2):199-211. PubMed ID: 30414802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.